George A. Samuel III

CIK: 0001878732

Transaction Breakdown

Open Market Buys (P)1 (11.1%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (22.2%)

Derivative conversions

Awards (A)3 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)3 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LCTX

Lineage Cell Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

LCTX
Lineage Cell Therapeutics, Inc.
Mar 5, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
900K shares-
LCTX
Lineage Cell Therapeutics, Inc.
Feb 11, 2026
Exercise(M)
Direct
6.1K shares-
LCTX
Lineage Cell Therapeutics, Inc.
Feb 11, 2026
Tax Payment(F)
Direct
2.5K shares at avg. $1.80$5K
LCTX
Lineage Cell Therapeutics, Inc.
Dec 19, 2025
Award(A)
Direct
1.7K shares-
LCTX
Lineage Cell Therapeutics, Inc.
Dec 19, 2025
Tax Payment(F)
Direct
65 shares at avg. $1.68$109.2
LCTX
Lineage Cell Therapeutics, Inc.
Mar 10, 2025
Award(A)
Employee Stock Option (Right to Buy)
Direct
750K shares-
LCTX
Lineage Cell Therapeutics, Inc.
Feb 11, 2025
Tax Payment(F)
Direct
2.4K shares at avg. $0.65$2K
LCTX
Lineage Cell Therapeutics, Inc.
Feb 11, 2025
Exercise(M)
Direct
6.1K shares-
LCTX
Lineage Cell Therapeutics, Inc.
Nov 26, 2024
Purchase(P)
Direct
15K shares at avg. $0.60$9K

		Type	Shares	Price		Ownership
Mar 5, 2026	LCTX Lineage Cell Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	900,000	-	-	Direct
Feb 11, 2026	LCTX Lineage Cell Therapeutics, Inc.	Exercise(M)	6,075	-	$0	Direct
Feb 11, 2026	LCTX Lineage Cell Therapeutics, Inc.	Tax Payment(F)	2,502	$1.80	$4,504	Direct
Dec 19, 2025	LCTX Lineage Cell Therapeutics, Inc.	Award(A)	1,735	-	-	Direct
Dec 19, 2025	LCTX Lineage Cell Therapeutics, Inc.	Tax Payment(F)	65	$1.68	$109	Direct
Mar 10, 2025	LCTX Lineage Cell Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	750,000	-	-	Direct
Feb 11, 2025	LCTX Lineage Cell Therapeutics, Inc.	Tax Payment(F)	2,440	$0.65	$1,586	Direct
Feb 11, 2025	LCTX Lineage Cell Therapeutics, Inc.	Exercise(M)	6,076	-	-	Direct
Nov 26, 2024	LCTX Lineage Cell Therapeutics, Inc.	Purchase(P)	15,000	$0.60	$9,000	Direct

1-9 of 9 transactions

About Samuel George A. III

Samuel George A. III (SEC CIK 0001878732) files insider reports with the SEC as General Counsel and Secretary of Lineage Cell Therapeutics, Inc. (LCTX).

Signal8 holds 6 ownership filings by Samuel George A. III, all Form 4s, filed between Nov 26, 2024 and Mar 6, 2026. Those filings report 9 transactions, from Nov 26, 2024 to Mar 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Samuel George A. III's filings is in CARLSBAD, CA.

Recent filings by Samuel George A. III

Mar 5, 2026: Grant or award of LCTX derivative securities (Form 4, code A).
Feb 11, 2026: Option exercise of LCTX shares (Form 4, code M).
Feb 11, 2026: Tax withholding of LCTX shares (Form 4, code F).
Dec 19, 2025: Grant or award of LCTX shares (Form 4, code A).
Dec 19, 2025: Tax withholding of LCTX shares (Form 4, code F).

Other insiders filing for Lineage Cell Therapeutics, Inc. (LCTX)

Bradsher Neal C, Director
Jayasuriya Anula, Director
Mulroy Michael H., Director
ANDREWS DEBORAH J, Director
Russell Angus C., Director
Amin Dipti, Director

How to read Form 4 transaction codes